FDA updates sotatercept-csrk label with HYPERION data, showing earlier use cuts PAH clinical worsening risk 76% alongside background therapy.
|Podcasts|October 7, 2015
An MD with RA Speaks on Chronic Pain Rx
Author(s)Liza Leal, MD
Advertisement
Liza Leal, MD knows something about pain, both professionally and personally as a patient. She lives with rheumatoid arthritis. Her personal experiences provide a unique perspective that strengthens her professional commitment to treat patients with compassion, understanding, and education.
In this podcast, Dr. Leal addresses these questions:
- What are some effective strategies when you think your patient with chronic pain is misusing his medications?
- Are there alternatives to urine drug screens?
- What are the options for patients who are opioid-dependent and who want to stop or decrease medications?
- What are the advantages of treatments such as buprenorphine, Butrans, Tramadol ER, compounded creams, counseling?
- What are the options for managing an intervention if a family or provider feels a patient may be misusing opioid medication?
Dr Leal is the author of Live Well With Chronic Pain, which she created as a tool for patients and physicians to better communicate with each other regarding chronic pain. Her website is
Advertisement
Related to this article
A US laboratory study found that 29.5% of patients with Lyme antibodies were seropositive for at least 1 other tick-borne pathogen.
Lumateperone reduced acute mania symptoms by day 3 in a phase 3 bipolar 1 trial, according to Johnson & Johnson.
Endocrine Society statement highlights key research gaps on obesity drugs—who benefits, long-term dosing, safety, and measuring success beyond weight loss.
Finerenone wins FDA clearance for type 1 diabetes–related CKD, lowering albuminuria in FINE-ONE and opening a long-awaited treatment path.
New American Society of Hematology guidelines raise ferritin cutoffs to catch iron deficiency sooner, including pregnancy and inflammation, and add TSAT for clearer diagnosis.
The US FDA cleared a novel insulin patch pump that can be used for up to 3 days with an additional 12-hour grace period in persons with diabetes.
Takeda’s oral TYK2 inhibitor showed rapid skin clearance in phase 3 psoriasis trials as FDA fast-tracks review; decision expected early 2027.
Advertisement
Advertisement
Trending on Patient Care Online
1
Lumateperone Reduces Acute Mania Symptoms in Phase 3 Bipolar I Trial
2
FDA Approves Sotatercept-csrk Label Update for Newly Diagnosed PAH
3
Endocrine Society Obesity Statement Calls for Goals Beyond Weight Loss
4
Clinical Inertia and Poor Measurement Technique Undermine BP Control
5